Oblimersen
Oblimersen
Oblimersen (pronounced oh-BLI-mer-sen) is a synthetic antisense oligodeoxynucleotide that has been used in the potential treatment of certain types of cancer, including melanoma and leukemia. It works by targeting and reducing the levels of Bcl-2, a protein that is overexpressed in some cancer cells and contributes to resistance against cancer treatments.
Etymology
The name "Oblimersen" is derived from the term "oligo", which refers to the short chain of nucleotides that make up the drug, and "mersen", which is a common suffix used in the naming of antisense drugs.
Mechanism of Action
Oblimersen is an antisense oligodeoxynucleotide that binds to the mRNA of the Bcl-2 gene. This binding triggers the degradation of the mRNA, thereby reducing the production of the Bcl-2 protein. By reducing the levels of Bcl-2, oblimersen may enhance the effectiveness of other cancer treatments, such as chemotherapy and radiation therapy.
Related Terms
- Antisense therapy: A type of treatment that uses antisense oligonucleotides, like oblimersen, to target and degrade specific mRNAs in the body.
- Oligonucleotide: A short chain of nucleotides, which are the building blocks of DNA and RNA.
- Bcl-2: A protein that is often overexpressed in cancer cells and contributes to resistance against cancer treatments.
See Also
External links
- Medical encyclopedia article on Oblimersen
- Wikipedia's article - Oblimersen
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski